Braak Staging and Tau Propagation Pathway

Overview

The Braak staging system, established by Heiko and Eva Braak in 1991, provides a standardized neuropathological framework for staging the progression of tau neurofibrillary tangles (NFTs) in Alzheimer’s disease (AD) and related tauopathies ^{1Neuropathological stageing of Alzheimer-related changes1991 · Acta Neuropathol. · DOI 10.1007/BF00308809Open reference}. This staging system has become one of the most influential diagnostic tools in neurodegeneration research, correlating strongly with clinical impairment and serving as a benchmark for in vivo biomarker validation.

Historical Background and Discovery

In their seminal 1991 publication, Braak and Braak systematically examined the distribution of tau pathology across 116 brains spanning the spectrum from clinically normal to severely demented individuals ^{1Neuropathological stageing of Alzheimer-related changes1991 · Acta Neuropathol. · DOI 10.1007/BF00308809Open reference}. Their key observation was that tau pathology does not spread randomly but follows a highly predictable, hierarchical pattern beginning in specific brain regions and progressing in a sequential manner. This pattern allowed them to define six stages of increasing pathological severity, now universally known as Braak stages I through VI.

The original Braak classification was based on examination of silver-stained tissue sections, primarily using the Gallyas silver impregnation method that selectively highlights neurofibrillary changes. This technique revealed the three characteristic tau-positive structures: (1) neurofibrillary tangles (NFTs) within neuronal perikarya and proximal dendrites, (2) neuropil threads (NTs) representing abnormal tau accumulation in distal dendrites and axons, and (3) cell processes surrounding neurons (dystrophic neurites).

The Six Braak Stages

Stage I: Transentorhinal (Clinically Silent)

Neuroanatomical Distribution:

• Pathology begins in the transentorhinal region (Brodmann area 35), a transitional zone between the entorhinal cortex and the parahippocampal gyrus

• Sparse NFTs appear in layer pre-α of the transentorhinal cortex

• Occasional involvement of the entorhinal cortex (Brodmann area 28), particularly in layer II

Clinical Significance:

• This stage represents the earliest detectable pathological changes

• Individuals at this stage are typically cognitively normal

• No clinical symptoms correlate with isolated transentorhinal pathology

• Estimated to occur approximately 15-20 years before clinical onset of AD

Stage II: Limbic (Early Symptomatic)

Neuroanatomical Distribution:

• Pathology extends into the entorhinal cortex bilaterally

• Initial spread to the hippocampal formation, particularly the CA1 region and subiculum

• Appearance of neuropil threads in the molecular layer of the dentate gyrus

• Involvement of the amygdala, especially the basolateral nuclei

Clinical Significance:

• May correspond to the earliest subtle cognitive changes, often termed subjective cognitive decline

• Some studies suggest subtle episodic memory deficits may be detectable with sensitive neuropsychological testing

• Often corresponds to the mild cognitive impairment (MCI) stage when progression halts

Stage III: Limbic (Moderate)

Neuroanatomical Distribution:

• Moderate to severe involvement of the entorhinal cortex and hippocampus

• Pathology spreads to the temporal isocortex (inferior temporal gyrus, temporal pole)

• Involvement of the amygdala and piriform cortex

• Initial appearance of NFTs in the basal forebrain cholinergic nuclei

Clinical Significance:

• Clear cognitive deficits, typically affecting episodic memory

• Diagnosis of MCI due to AD is common at this stage

• Strong correlation between NFT density and memory impairment

• Amyloid pathology typically present by this stage (Thal phase 3-4)

Stage IV: Limbic (Severe)

Neuroanatomical Distribution:

• Heavy burden throughout the limbic system

• Marked involvement of the hippocampus (CA1, subiculum, dentate gyrus)

• Severe pathology in the entorhinal and perirhinal cortices

• Extension into the temporal association cortex

Clinical Significance:

• Moderate dementia typically present

• Memory impairment is pronounced

• Other cognitive domains beginning to show deficits (executive function, visuospatial)

• Strong correlation between Braak stage and clinical dementia severity

Stage V: Neocortical (Early Neocortical)

Neuroanatomical Distribution:

• Pathology spreads to the association isocortex

• Significant involvement of parietal association cortex (superior and inferior parietal lobules)

• Prefrontal cortex showing moderate pathology

• Posterior cingulate cortex and precuneus involved

Clinical Significance:

• Moderate to severe dementia

• Multiple cognitive domains impaired

• Loss of independence in daily activities

• Global cognitive impairment (MMSE typically <20)

Stage VI: Neocortical (Severe Neocortical)

Neuroanatomical Distribution:

• Primary motor and sensory cortices become involved

• Pathology extends to the occipital cortex (especially primary visual cortex)

• Subcortical nuclei affected, including the caudate nucleus and globus pallidus

• Complete destruction of the six-layered neocortex

Clinical Significance:

• Severe dementia (MMSE typically <10)

• Complete loss of cognitive function

• Motor symptoms may emerge (parkinsonism, pseudobulbar signs)

• Patient typically requiring full-time care

Mechanisms of Tau Propagation

Prion-like Spread Hypothesis

The hierarchical progression of tau pathology observed in Braak staging suggests that tau pathology spreads between anatomically connected brain regions. This has led to the hypothesis that pathological tau may propagate in a prion-like manner, with tau aggregates serving as templates that recruit and convert normal tau proteins into the pathological form ^{2Prion-like mechanisms in neurodegenerative diseases2009 · Nat Rev Neurosci. · DOI 10.1038/nrn.2009.188Open reference}.

Key evidence supporting prion-like propagation:

1. Tau aggregates can be transmitted experimentally: Injection of brain homogenate containing tau aggregates into naive animals induces tau pathology at the injection site and sometimes at connected regions ^{3Transmission and spreading of tauopathy in transgenic mouse brain2009 · Nat Cell Biol. · DOI 10.1038/nature08689Open reference}

2. Tau appears in the extracellular space: Tau is released from neurons through multiple mechanisms including exocytosis, active secretion, and cell death, making it available for uptake by neighboring cells ^{4'The secretion of tau: physiological and pathological mechanisms'2022 · Acta Neuropathol. · DOI 10.1007/s00401-022-02387-8Open reference}

3. Tau can be taken up by naive neurons: Extracellular tau can enter neurons through various endocytic mechanisms and templated aggregation can occur inside the recipient cell ^{5Neuronal activity promotes tau pathology via adaptive secretory mechanisms2016 · Nat Neurosci. · DOI 10.1038/nn.4284Open reference}

4. Tau pathology follows neural networks: The progression pattern correlates with functional and anatomical connectivity between brain regions, as demonstrated by modern connectomics studies ^{6Predicting regional neurodegeneration from the healthy brain functional connectome2012 · Neuron. · DOI 10.1016/j.neuron.2012.03.004Open reference}

Cell-to-Cell Transmission Mechanisms

Release mechanisms:

• Exosomal release: Tau can be packaged into exosomes and released from neurons ^{7The release and trans-synaptic transmission of tau via exosomes2017 · J Neurochem. · DOI 10.1111/jnc.13982Open reference}

• Direct secretion: Tau is actively secreted in a free form, possibly through unconventional secretory pathways

• Necrosis/neuropil damage: Release from dying neurons

Uptake mechanisms:

• Heparan sulfate proteoglycans (HSPGs): Cell surface HSPGs facilitate tau internalization ^{8Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds2013 · Proc Natl Acad Sci USA. · DOI 10.1073/pnas.1301440110Open reference}

• Receptor-mediated endocytosis: Various neuronal receptors can mediate tau uptake

• Macropinocytosis: Large-scale fluid-phase uptake of extracellular material

Intracellular trafficking:

• Endosomal trafficking of internalized tau

• Retrograde transport to the soma

• Templated aggregation in the cytosol

Spreading Patterns and Network Biology

Modern neuroimaging studies have confirmed that tau accumulation follows patterns consistent with the spread along neural pathways:

Relationship to Other Pathological Staging Systems

Braak vs. Thal Phases (Amyloid)

While Braak staging describes tau pathology, the Thal phases describe the spread of amyloid-beta plaques:

The typical sequence shows amyloid appearing first (Thal 1-2) followed by tau pathology (Braak I-II), suggesting amyloid may drive tau pathology rather than vice versa.

Braak vs. CERAD (Neuritic Plaques)

The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) scores neuritic plaque density:

The combination of Braak stage, Thal phase, and CERAD score forms the ABC score of AD neuropathology, providing a comprehensive pathological diagnosis.

Relationship to Clinical Syndromes

Typical amnestic AD: Correspond to Braak III-IV with Thal 3, CERAD moderate-frequent

Posterior cortical atrophy: Often shows early tau burden in occipital and parietal regions with relative sparing of medial temporal lobe initially

Logopenic progressive aphasia: Left temporal-parietal predominance of tau

Behavioral variant FTD: May show frontal predominant tau or TDP-43 pathology depending on subtype

In Vivo Biomarker Correlation with Braak Stages

CSF Biomarkers

Tau PET Imaging

Tau PET ligands now allow in vivo visualization of Braak-like staging:

Integration of Biomarkers

Modern biomarker models propose a temporal sequence:

1. Preclinical: Elevated p-tau231 in CSF → p-tau217 in plasma

2. MCI: Positive tau PET in entorhinal cortex (Braak I-II)

3. Mild AD: Tau PET spreads to limbic regions (Braak III-IV)

4. Moderate AD: Tau PET in association cortices (Braak V)

5. Severe AD: Widespread cortical and subcortical involvement (Braak VI)

Tau Propagation in Primary Tauopathies

While Braak staging was developed for AD, similar staging systems exist for other tauopathies:

Progressive Supranuclear Palsy (PSP)

• Pathology begins in the basal ganglia and brainstem

• Spreads to the globus pallidus, subthalamic nucleus

• Later involves the frontal cortex and cerebellum

• Different from AD pattern despite both being 4R tauopathies

Corticobasal Degeneration (CBD)

• Asymmetrical onset affecting one side

• Early involvement of motor cortex and basal ganglia

• Spread to contralateral cortex as disease progresses

• Variable patterns depending on clinical phenotype

Pick’s Disease (3R Tauopathy)

• Initially localized to frontal and temporal cortices

• Prominent Gallyas-positive Pick bodies

• Relative sparing of the hippocampus early

• Different propagation pattern from AD

Tau Spreading and Seeding in CBS/PSP

The spreading and seeding mechanisms in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) represent critical therapeutic targets. Unlike Alzheimer’s disease, these 4R tauopathies exhibit distinct propagation patterns that reflect their underlying tau strain properties.

Prion-Like Propagation in 4R Tauopathies

Both CBS and PSP demonstrate prion-like propagation characteristics, where pathological tau seeds template the conversion of normal tau in recipient cells. The key mechanisms include:

1. Template-Based Conversion: Pathological tau aggregates recruit and convert normal tau monomers into the misfolded conformation, creating self-propagating aggregates.

2. Strain-Specific Properties: PSP and CBD tau strains exhibit distinct conformations determined by cryo-EM studies, with predominant 4R tau incorporation and characteristic filament morphologies (straight filaments in PSP, twisted ribbons in CBD).

3. Intercellular Transfer: Multiple pathways facilitate tau spread between neurons:

   • Trans-synaptic transmission: Tau travels along neuronal connections

   • Extracellular vesicles: Exosomes and microvesicles contain tau species

   • Direct uptake: Heparan sulfate proteoglycans (HSPGs) mediate cellular internalization

Extracellular Tau in CBS/PSP

The extracellular tau pool serves as both a biomarker and therapeutic target:

Tau Oligomer Seeds in CBS/PSP

Tau oligomers represent the most toxic and seeding-competent species:

1. Oligomer Characteristics:

   • PSP tau oligomers are predominantly 3-6mers (smaller than AD oligomers)

   • pS356 phosphorylation enriched in PSP-specific oligomers

   • High cellular toxicity compared to filamentary forms

2. Seeding Mechanisms:

   • Oligomers enter neurons via HSPG-mediated endocytosis

   • Template-assisted recruitment of intracellular tau

   • Efficient cross-species seeding in cellular models

3. Regional Spread Patterns:

   • PSP: Brainstem → basal ganglia → cortical regions

   • CBS: Asymmetric cortical/subcortical spread from onset

Therapeutic Implications for CBS/PSP

Understanding propagation mechanisms informs therapeutic development:

• Anti-tau antibodies (e.g., E2814, BIIB080): Target extracellular tau to block propagation

• Oligomerization inhibitors: Prevent toxic oligomer formation

• HSPG antagonists: Block cellular uptake of pathological tau

• ASO therapy: Reduce total tau substrate available for seeding

Therapeutic Implications

Targeting Tau Propagation

Understanding Braak staging and propagation mechanisms has guided therapeutic development:

Staging-Based Clinical Trials

Clinical trials increasingly use biomarker staging to select patients:

• Early stage trials (Braak I-II): Focus on prevention; require biomarker confirmation of low tau burden

• Mid-stage trials (Braak III-IV): Primary target for disease-modifying therapies

• Late-stage trials (Braak V-VI): May be too late for meaningful intervention

Precision Medicine Approaches

Emerging approaches target specific propagation mechanisms:

• HSPG antagonists: Block tau uptake ^{1Neuropathological stageing of Alzheimer-related changes1991 · Acta Neuropathol. · DOI 10.1007/BF00308809Open reference}4

• Exosome inhibitors: Prevent tau release via exosomes

• Kinase inhibitors: Prevent tau phosphorylation that promotes aggregation

Tau Propagation Models

Sequential Model

graph TD
    A["Normal Tau"] -->|"Hyperphosphorylation"| B["p-Tau"]
    B -->|"Detachment"| C["Tau Oligomers"]
    C -->|"Aggregation"| D["PHFs/NFTs"]
    D -->|"Release"| E["Extracellular Tau"]
    E -->|"Uptake"| F["Neighbor Neuron"]
    F -->|"Templating"| G["New p-Tau"]
    G --> C

    style A fill:#0a1f0a
    style B fill:#3e2200
    style C fill:#2d0f0f
    style D fill:#1a0a1f
    style E fill:#0a1929
    style F fill:#002f33
    style G fill:#1e1e2e8e1

Network Diffusion Model

Tau burden correlates with the pattern of brain connectivity:

1. Vulnerable nodes: High connectivity regions show earlier and more severe tau

2. Network epicenters: Certain hub regions (e.g., entorhinal cortex) serve as propagation origins

3. Connected spread: Tau follows anatomical pathways rather than random diffusion

Research Frontiers

Open Questions

1. What initiates tau pathology? The trigger for initial tau hyperphosphorylation remains unknown

2. What determines propagation speed? Some patients show rapid progression, others remain stable for years

3. Can propagation be halted? No therapy has yet demonstrated clear effects on tau spread

4. What explains regional vulnerability? Why does entorhinal cortex show earliest changes?

Emerging Research Areas

• Tau strains: Different conformations may have different propagation characteristics ^{1Neuropathological stageing of Alzheimer-related changes1991 · Acta Neuropathol. · DOI 10.1007/BF00308809Open reference}5

• Microglial role: Evidence suggests microglia may facilitate or inhibit spread

• Sleep and tau: Sleep disruption accelerates tau propagation ^{1Neuropathological stageing of Alzheimer-related changes1991 · Acta Neuropathol. · DOI 10.1007/BF00308809Open reference}6

• Vascular factors: Perivascular spaces may serve as propagation pathways

Cross-References

Related Mechanisms

• Tau Pathology — Overview of tau pathology in neurodegeneration

• Tau Hyperphosphorylation — Mechanisms of tau phosphorylation

• Tau Propagation Hypothesis — Alternative models of tau spread

• Prion-Like Spreading — General mechanism of protein aggregate spread

Related Proteins

• Tau Protein — The microtubule-associated protein

• MAPT Gene — The tau encoding gene

Related Diseases

• Alzheimer’s Disease — Primary disease context for Braak staging

• Progressive Supranuclear Palsy — 4R tauopathy

• Corticobasal Degeneration — Atypical tauopathy

Related Therapeutics

• Tau Immunotherapy — Anti-tau antibody approaches

• Tau Aggregation Inhibitors — Small molecule approaches

• Tau PET Imaging — In vivo tau visualization

See Also

• Tau Pathology

• Tau Hyperphosphorylation

• Tau Propagation Hypothesis

• Prion-Like Spreading

• Tau Protein

• MAPT Gene

• Alzheimer’s Disease

• Progressive Supranuclear Palsy

• Corticobasal Degeneration

External Links

• PubMed

• KEGG Pathways

Regional Vulnerability and Selective Neuronal Loss

Why the Entorhinal Cortex?

The transentorhinal region and entorhinal cortex show the earliest tau pathology for several interconnected reasons. First, these regions represent the primary gateway between the hippocampus and the neocortex, receiving massive inputs from multiple association cortices. This high connectivity makes them exposed to high levels of neuronal activity and metabolic demand. Second, the layer II neurons of the entorhinal cortex, which are selectively vulnerable, have distinctive electrophysiological properties that may predispose them to tau pathology. Third, these neurons express high levels of tau isoforms and have specific phosphorylation patterns that may facilitate early pathological changes. Finally, evidence suggests that the transentorhinal cortex has unique protein processing characteristics that make it particularly susceptible to tau aggregation.

Neuronal Subtypes and Vulnerability

Specific neuronal populations show differential vulnerability to tau pathology:

Vulnerable populations:

• Layer II entorhinal neurons: The most consistently affected in early Braak stages

• CA1 pyramidal neurons: Severe involvement from Braak III onward

• Subicular neurons: Early to moderate involvement

• Layer V pyramidal neurons: Affected in later stages

Relatively resistant populations:

• GABAergic interneurons: Generally spared until late stages

• Cerebellar Purkinje cells: Typically unaffected in pure AD

• Brainstem monoaminergic neurons: Variable involvement depending on disease variant

Structural Correlates of Propagation

The spread of tau pathology follows both anatomical connectivity and regional vulnerability factors:

Anatomical pathways:

• Perforant path: Major connection from entorhinal cortex to hippocampus

• Temporoammonic path: Direct CA1 connections

• Associational connections: Neocortical spread within temporal lobe

Vulnerability factors:

• High metabolic rate

• Elevated oxidative stress

• Mitochondrial dysfunction

• Calcium dysregulation

Methodological Considerations

Assessment Methods

The original Braak staging was based on silver staining, but modern approaches include:

1. Immunohistochemistry: Phospho-tau specific antibodies (AT8, AT100, PHF-1)

2. Biochemical analysis: Tau species in brain homogenates

3. Mass spectrometry: Precise tau isoform quantification

4. Cryo-EM: Filament structure analysis

5. Tau PET: In vivo visualization

Limitations and Criticisms

Despite its widespread use, Braak staging has limitations:

1. Binary staging: Does not capture continuous nature of pathology

2. Regional specificity: May not reflect individual variations

3. Comorbidities: Does not account for mixed pathology (LBD, TDP-43)

4. Sex differences: Potential differences in progression patterns

5. Age effects: Normal aging-related tau changes vs. pathological

Alternative Staging Approaches

Modern proposals include:

• Quantitative assessment: Continuous measures of tau burden

• Network-based staging: Using connectomics data

• Multimodal integration: Combining PET, CSF, and MRI

• Individualized trajectories: Personalized staging models

Tau Species and Propagation

Different Tau Aggregate Types

Tau pathology exists in multiple forms that may have different propagation properties:

Soluble species:

• Monomeric tau (normal and modified)

• Oligomeric tau (toxic intermediate)

• Phosphorylated tau (pathological but not aggregated)

Insoluble species:

• Paired helical filaments (PHFs) - classic AD

• Straight filaments (SFs) - seen in some tauopathies

• NFTs (intracellular inclusions)

• Ghost tangles (extracellular)

Seeding Competence

Not all tau species can template the conversion of normal tau:

• Seed-competent tau: Can induce aggregation in naive cells

• Non-seed-competent: Cannot template conversion

• Strain-specific: Different conformations have different seeding properties

The microtubule-binding repeat region (MTBR) is critical for seeding activity. Cryo-EM studies show that the MTBR forms the core of tau filaments, with disease-specific folds determining seeding properties.

Clinical Correlations

Cognitive Implications by Stage

Progression Rates

Longitudinal studies reveal variable progression:

• Fast progressors: 1-2 years between stages

• Typical progressors: 2-3 years between stages

• Slow progressors: >3 years between stages

Factors influencing rate include:

• Age at onset

• Genetic factors (APOE status)

• Comorbidities

• Education/cognitive reserve

Biomarker Progression Model

Modern biomarker models integrate multiple measures:

1. Preclinical (Braak I-II): Elevated CSF p-tau, negative PET

2. Prodromal (Braak III-IV): Positive PET in entorhinal/hippocampus

3. Dementia (Braak V-VI): Widespread cortical PET signal

Future Directions and Research Gaps

Unresolved Questions

1. Primary trigger: What initiates the first tau pathology?

2. Propagation drivers: What determines the speed and pattern of spread?

3. Cell-type specificity: Why are certain neurons selectively vulnerable?

4. Therapeutic windows: When is intervention most effective?

5. Biomarker validation: Can we detect Braak I-II in vivo?

Emerging Technologies

• Super-resolution microscopy: Visualize tau at nanoscale

• Single-cell sequencing: Cell-type specific tau expression

• Organoid models: Human brain models for propagation studies

• Computational modeling: Predictive progression models

Integration with Other Pathologies

Modern understanding emphasizes that AD involves multiple co-occurring pathologies:

• Amyloid-beta plaques (Thal phases)

• Tau tangles (Braak stages)

• TDP-43 inclusions ( limbic predominant age-related TDP-43)

• Alpha-synuclein (Lewy bodies)

• Vascular pathology

The interaction between these pathologies influences progression and clinical expression.

Regional Brain Maps

Key Regions in Tau Propagation

Conclusion

The Braak staging system remains the cornerstone of tau pathology assessment in Alzheimer’s disease and related disorders. Its strong clinical correlation, pathological specificity, and biomarker validation make it essential for research and clinical practice. Understanding the mechanisms underlying the predictable progression pattern—whether through prion-like propagation, network-based spread, or selective neuronal vulnerability—will be critical for developing effective disease-modifying therapies. The integration of in vivo biomarkers with neuropathological staging provides unprecedented opportunities to detect early changes, track progression, and select patients for clinical trials. Future research should focus on understanding the earliest triggers of tau pathology, developing interventions that can halt or slow propagation, and personalizing treatment approaches based on individual biomarker profiles.

Confidence Assessment

🟢 High Confidence

Overall Confidence: 90%